Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.

Global Acquisition Expands Ferring's Role in Women's Health

SAINT-PREX, Switzerland, May 10, 2010 - Ferring Pharmaceuticals today announced an agreement that will expand its
Women's Health product portfolio with the acquisition of the global rights to
Xanodyne Pharmaceutical's LYSTEDA(TM) (tranexamic acid), a first-in-class,
non-hormonal therapy indicated specifically for treatment of women with
cyclic heavy menstrual bleeding (HMB). The company will initially market
LYSTEDA in the U.S., and is evaluating opportunities in other markets.
LYSTEDA oral tablets received approval on November 13, 2009 following a
Priority Review by the U.S. Food and Drug Administration (FDA). It is
estimated that up to 22 million women suffer from HMB in the U.S.(1,2)

(Logo: www.newscom.com/cgi-bin/prnh/20100510/NY01272LOGO )

"Ferring, as a global, privately held biopharmaceutical company, has a
long-standing commitment to the health of women worldwide," said Michel L.
Pettigrew, President of the Executive Board, and President and CEO, Ferring
Holding Inc. "The acquisition of LYSTEDA, in addition to our ongoing support
of research and medical education in the field of Reproductive Health,
demonstrates this significant commitment and represents an important addition
to our Women's Health portfolio."

Added Olivier Delannoy, Vice President, U.S. Infertility Business Unit,
"In the U.S., the acquisition of LYSTEDA enables us to expand into the field
of obstetrics and gynecology. Ferring is a well-established leader in
reproductive endocrinology with the broadest portfolio of infertility
treatments in the U.S., including MENOPUR(R), BRAVELLE(R) and ENDOMETRIN(R).
The addition of LYSTEDA furthers our goal of providing treatments for every
stage of a woman's reproductive health, including before, during and after
pregnancy."

Ferring will introduce LYSTEDA to the Obstetric and Gynecology community
at the upcoming American College of Obstetricians and Gynecologists (ACOG)
58th Annual Clinical Meeting, May 15-19, 2010 in San Francisco. For more
information, visit www.lysteda.com.

About LYSTEDA(TM)

LYSTEDA(TM) (tranexamic acid) tablets are indicated for the treatment of
cyclic heavy menstrual bleeding. Prior to prescribing LYSTEDA, exclude
endometrial pathology that can be associated with heavy menstrual bleeding.

Important Safety Information

Do not prescribe LYSTEDA to women who are known to have: active
thromboembolic disease, a history of thrombosis or thromboembolism, including
retinal vein or artery occlusion, an intrinsic risk of thrombosis or
thromboembolism. Venous and arterial thrombosis or thromboembolism, and
retinal artery and retinal vein occlusions, have been reported with
tranexamic acid.

Do not prescribe LYSTEDA to women with known hypersensitivity to
tranexamic acid.

Because LYSTEDA is antifibrinolytic, concomitant use with hormonal
contraception may exacerbate the increased thrombotic risk (blood clots,
stroke, and myocardial infarction) associated with combination hormonal
contraceptives. Women using hormonal contraception should use LYSTEDA only if
there is a strong medical need and the treatment benefit will outweigh the
potential increased risk of a thrombotic event.

In case of severe allergic reaction, discontinue LYSTEDA and seek
immediate medical attention. A case of severe allergic reaction (dyspnea,
tightening of the throat, and facial flushing) to LYSTEDA was reported in
clinical trials and a case of anaphylactic shock was reported in the
literature, involving a patient who received an intravenous bolus of
tranexamic acid.

Retinal venous and arterial occlusion has been reported in patients using
tranexamic acid. Immediately discontinue LYSTEDA if visual or ocular symptoms
occur. Ligneous conjunctivitis also has been reported in patients taking
tranexamic acid which resolved with drug discontinuation.

LYSTEDA is not recommended for women taking either Factor IX complex
concentrates or antiinhibitor coagulant concentrates because the risk of
thrombosis may be increased.

Exercise caution when prescribing LYSTEDA to women with acute
promyelocytic leukemia taking all-trans retinoic acid for remission induction
because of possible exacerbation of the procoagulant effect of all-trans
retinoic acid.

Cerebral edema and cerebral infarction may be caused by use of LYSTEDA in
women with subarachnoid hemorrhage.

The most common adverse reactions in clinical trials (> 5%, and more
frequent in LYSTEDA subjects compared to placebo subjects) were: headache,
sinus and nasal symptoms, back pain, abdominal pain, musculoskeletal pain,
arthralgia, muscle cramps and spasms, migraine, anemia and fatigue.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, headquartered in Switzerland, is a privately
owned, research driven specialty biopharmaceutical group active in global
markets. The company identifies, develops and markets innovative products in
the areas of endocrinology, gastroenterology, gynaecology, fertility and
urology. Ferring Pharmaceuticals Inc. offers a line of products in the U.S.
market. They include: BRAVELLE(R) (urofollitropin for injection, purified),
MENOPUR(R) (menotropins for injection, USP) and REPRONEX(R) (menotropins for
injection, USP), Novarel(R) (chorionic gonadotropin for injection, USP),
ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg, FIRMAGON(R) (degarelix
for injection), PROSED(R) DS (methenamine, phenyl salicylate, methylene blue,
benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA(R) (1% sodium
hyaluronate).

To learn more about Ferring or its products please visit
www.ferring.com. For U.S.-specific information, call 1-888-FERRING
(1-888-337-7464) or visit www.FerringUSA.com.

(1) U.S. Census Bureau, 2006-2008 American Community Survey. Available
at: factfinder.census.gov/. Accessed April 7, 2010.

(2) Tufts Medical Center website. Heavy Menstrual Bleeding. Available at:
www.tufts-nemc.org. Accessed April 7, 2010.

Andrea Preston (U.S. inquiries), Kovak-Likly Communications, +1-203-762-8833, or Fax: +1-203-762-9195, apreston at klcpr.com; or Helen Gallagher (Global/European inquiries), Ferring Pharmaceuticals, +41-58-301-00-51, or Fax: +41-58-301-00-39, helen.gallagher at ferring.com